These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 3523506

  • 1. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M.
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract] [Full Text] [Related]

  • 2. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV, Brinn RU, Gram LF.
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [Abstract] [Full Text] [Related]

  • 3. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM.
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract] [Full Text] [Related]

  • 4. Polymorphic drug oxidation in humans.
    Eichelbaum M.
    Fed Proc; 1984 May 15; 43(8):2298-302. PubMed ID: 6714436
    [Abstract] [Full Text] [Related]

  • 5. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
    Eichelbaum M.
    Internist (Berl); 1983 Mar 15; 24(3):117-27. PubMed ID: 6135670
    [No Abstract] [Full Text] [Related]

  • 6. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
    Inaba T, Tyndale RE, Mahon WA.
    Br J Clin Pharmacol; 1986 Aug 15; 22(2):199-200. PubMed ID: 3756068
    [No Abstract] [Full Text] [Related]

  • 7. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P, Kronbach T, Eichelbaum M, Meyer UA.
    Biochem Pharmacol; 1987 Dec 01; 36(23):4145-52. PubMed ID: 3689440
    [Abstract] [Full Text] [Related]

  • 8. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
    Tyndale RF, Inaba T, Kalow W.
    Drug Metab Dispos; 1989 Dec 01; 17(3):334-40. PubMed ID: 2568917
    [Abstract] [Full Text] [Related]

  • 9. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
    Gut J, Catin T, Dayer P, Kronbach T, Zanger U, Meyer UA.
    J Biol Chem; 1986 Sep 05; 261(25):11734-43. PubMed ID: 3745165
    [Abstract] [Full Text] [Related]

  • 10. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU.
    Eur J Clin Pharmacol; 1980 Feb 05; 17(2):153-5. PubMed ID: 7371707
    [Abstract] [Full Text] [Related]

  • 11. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
    Inaba T, Nakano M, Otton SV, Mahon WA, Kalow W.
    Can J Physiol Pharmacol; 1984 Jul 05; 62(7):860-2. PubMed ID: 6498616
    [Abstract] [Full Text] [Related]

  • 12. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
    Boobis AR, Murray S, Kahn GC, Robertz GM, Davies DS.
    Mol Pharmacol; 1983 Mar 05; 23(2):474-81. PubMed ID: 6220203
    [Abstract] [Full Text] [Related]

  • 13. [Clinical aspects of the polymorphism of oxidation phenotype].
    Mrozikiewicz PM.
    Pol Tyg Lek; 1983 Mar 05; 47(27-28):608-10. PubMed ID: 1488339
    [No Abstract] [Full Text] [Related]

  • 14. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M, Bertilsson L, Säwe J, Zekorn C.
    Clin Pharmacol Ther; 1982 Feb 05; 31(2):184-6. PubMed ID: 7056024
    [Abstract] [Full Text] [Related]

  • 15. Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.
    Clark DW, Edwards IR.
    Med Toxicol Adverse Drug Exp; 1988 Feb 05; 3(3):241-7. PubMed ID: 3398777
    [Abstract] [Full Text] [Related]

  • 16. Deficient metabolism of debrisoquine and sparteine.
    Inaba T, Otton SV, Kalow W.
    Clin Pharmacol Ther; 1980 Apr 05; 27(4):547-9. PubMed ID: 7357813
    [Abstract] [Full Text] [Related]

  • 17. Comparative pharmacogenetics of sparteine and debrisoquine.
    Inaba T, Vinks A, Otton SV, Kalow W.
    Clin Pharmacol Ther; 1983 Mar 05; 33(3):394-9. PubMed ID: 6825393
    [Abstract] [Full Text] [Related]

  • 18. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R, Meyer UA.
    Biochem Pharmacol; 1988 Oct 15; 37(20):3829-35. PubMed ID: 2903741
    [Abstract] [Full Text] [Related]

  • 19. [Role of pharmacogenetics in psychopharmacotherapy].
    Gram LF.
    Encephale; 1991 Oct 15; 17 Spec No 1():123-5. PubMed ID: 1864259
    [Abstract] [Full Text] [Related]

  • 20. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K, Gram LF.
    Eur J Clin Pharmacol; 1989 Oct 15; 36(6):537-47. PubMed ID: 2570698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.